Enliven Research Development from 2010 to 2026
| ELVN Stock | 29.42 2.43 9.00% |
Research Development | First Reported 2019-03-31 | Previous Quarter 21.5 M | Current Value 18.2 M | Quarterly Volatility 6.5 M |
Check Enliven Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enliven Therapeutics' main balance sheet or income statement drivers, such as Other Operating Expenses of 126.2 M, Research Development of 97.5 M or Total Operating Expenses of 126.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.23. Enliven financial statements analysis is a perfect complement when working with Enliven Therapeutics Valuation or Volatility modules.
Enliven | Research Development | Build AI portfolio with Enliven Stock |
Evaluating Enliven Therapeutics's Research Development across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Enliven Therapeutics's fundamental strength.
Latest Enliven Therapeutics' Research Development Growth Pattern
Below is the plot of the Research Development of Enliven Therapeutics over the last few years. It is Enliven Therapeutics' Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Enliven Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Research Development | 10 Years Trend |
|
Research Development |
| Timeline |
Enliven Research Development Regression Statistics
| Arithmetic Mean | 28,594,949 | |
| Geometric Mean | 16,679,428 | |
| Coefficient Of Variation | 115.05 | |
| Mean Deviation | 26,333,340 | |
| Median | 8,239,000 | |
| Standard Deviation | 32,899,537 | |
| Sample Variance | 1082.4T | |
| Range | 89.6M | |
| R-Value | 0.82 | |
| Mean Square Error | 382.2T | |
| R-Squared | 0.67 | |
| Significance | 0.00006 | |
| Slope | 5,328,597 | |
| Total Sum of Squares | 17318.1T |
Enliven Research Development History
About Enliven Therapeutics Financial Statements
Enliven Therapeutics investors utilize fundamental indicators, such as Research Development, to predict how Enliven Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Research Development | 92.9 M | 97.5 M |
Pair Trading with Enliven Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enliven Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enliven Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Enliven Stock
Moving against Enliven Stock
| 0.67 | HPQ | HP Inc | PairCorr |
| 0.64 | MSFT | Microsoft | PairCorr |
| 0.48 | BKNG | Booking Holdings | PairCorr |
| 0.39 | BAC | Bank of America Aggressive Push | PairCorr |
| 0.34 | BRK-A | Berkshire Hathaway | PairCorr |
The ability to find closely correlated positions to Enliven Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enliven Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enliven Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enliven Therapeutics to buy it.
The correlation of Enliven Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enliven Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enliven Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enliven Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Enliven Therapeutics Correlation against competitors. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Will Pharmaceuticals sector continue expanding? Could Enliven diversify its offerings? Factors like these will boost the valuation of Enliven Therapeutics. Projected growth potential of Enliven fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Enliven Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Enliven Therapeutics requires distinguishing between market price and book value, where the latter reflects Enliven's accounting equity. The concept of intrinsic value - what Enliven Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Enliven Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Enliven Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Enliven Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Enliven Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.